Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Genetic Signatures Ltd. ( (AU:GSS) ) has issued an announcement.
Genetic Signatures Ltd has updated the remuneration for its CEO, Allison Rossiter, with a new base salary of A$515,000 per annum and a long-term incentive plan involving performance rights. These changes, effective from October 2025, are part of a board review and aim to align the CEO’s compensation with long-term service and performance goals.
The most recent analyst rating on (AU:GSS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
More about Genetic Signatures Ltd.
Genetic Signatures is a specialist molecular diagnostics company focused on developing and commercializing its proprietary 3base® platform technology. The company designs and manufactures real-time PCR-based products under the EasyScreen™ brand for detecting infectious diseases. Its target markets include major hospitals and pathology laboratories, with a focus on rapidly screening for a wide array of infectious pathogens.
Average Trading Volume: 171,546
Technical Sentiment Signal: Sell
Current Market Cap: A$72.68M
For detailed information about GSS stock, go to TipRanks’ Stock Analysis page.